Target intelligence / Profile preview

Ebola virus glycoprotein GP2 fusion loop (EBOV GP2 FL)

Target
EBOV GP2 FL
Molecular classification
Viral envelope protein, Class I viral fusion protein, Glycoprotein, Type I transmembrane protein
01

Overview

The Ebola virus glycoprotein (GP) is the sole protein on the viral surface, existing as a trimer of GP1-GP2 heterodimers that mediates attachment and entry into host cells (UniProt P87666). The GP2 subunit contains a highly conserved hydrophobic region known as the fusion loop (FL), which is essential for the fusion of the viral envelope with the host endosomal membrane (Misasi & Sullivan, 2021). During the infection process, the GP1 subunit is cleaved by host endosomal proteases (cathepsins), exposing the GP2 fusion loop. This exposure allows the loop to insert into the host membrane, triggering a conformational change that facilitates viral entry into the cytoplasm. Because the fusion loop sequence is highly conserved across different ebolavirus species, it is a primary target for broadly neutralizing antibodies (bNAbs) such as ADI-15878 and CA45, which can neutralize multiple strains of the virus (Wec et al., 2017; Zhao et al., 2017). These antibodies typically function by preventing the structural transitions of GP2 required for membrane fusion.

Other names
Ebola virus GP2 fusion peptideGP2 internal fusion loopEBOV GP2 IFLEbolavirus GP2 fusion loop epitopeGP2-FL
02

Mechanism of action

Neutralization of viral infectivity by binding to the conserved fusion loop, thereby preventing the conformational transition of GP2 and the subsequent fusion of the viral envelope with the host endosomal membrane (Wec et al., 2017; Zhao et al., 2017).

03

Biological functions

Viral entryMembrane fusionHost cell attachmentEndosomal escape
04

Disease associations

Ebola virus diseaseViral infectionViral hemorrhagic fever
05

Safety considerations

Viral mutational escapeEndosomal delivery requirementsCross-reactivity challenges among ebolavirus species (Misasi & Sullivan, 2021)
06

Interacting drugs

ADI-15878

4 more in the full profile.

07

Biomarkers

Ebola virus RNA levelsGP-specific IgG titersNeutralizing antibody titers

Beyond the preview

Go deeper on Ebola virus glycoprotein GP2 fusion loop (EBOV GP2 FL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebola virus glycoprotein GP2 fusion loop (EBOV GP2 FL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call